Gerber Kawasaki Wealth & Investment Management Has $1.47 Million Stake in Stryker Co. (NYSE:SYK)

Gerber Kawasaki Wealth & Investment Management increased its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 158.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,092 shares of the medical technology company's stock after buying an additional 2,511 shares during the quarter. Gerber Kawasaki Wealth & Investment Management's holdings in Stryker were worth $1,474,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in SYK. Kohmann Bosshard Financial Services LLC bought a new position in shares of Stryker in the fourth quarter worth $25,000. Rakuten Securities Inc. grew its stake in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after buying an additional 68 shares in the last quarter. Centricity Wealth Management LLC bought a new position in Stryker in the 4th quarter valued at about $30,000. BankPlus Trust Department acquired a new position in shares of Stryker in the 4th quarter valued at approximately $33,000. Finally, Activest Wealth Management bought a new stake in shares of Stryker during the 4th quarter worth approximately $36,000. Institutional investors own 77.09% of the company's stock.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company's stock.

Stryker Price Performance

Shares of SYK opened at $365.34 on Friday. The business has a 50-day moving average of $367.81 and a 200-day moving average of $373.30. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a market capitalization of $139.45 billion, a price-to-earnings ratio of 47.08, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the business posted $3.46 earnings per share. As a group, equities research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. Stryker's payout ratio is currently 43.30%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SYK. Canaccord Genuity Group boosted their price objective on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Citigroup reissued a "buy" rating and set a $450.00 price target on shares of Stryker in a report on Wednesday, February 26th. Truist Financial raised their price objective on Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a research note on Thursday, January 30th. BTIG Research set a $403.00 target price on Stryker and gave the stock a "buy" rating in a research note on Monday, April 14th. Finally, Royal Bank of Canada raised their price target on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and an average price target of $423.53.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.